128 related articles for article (PubMed ID: 25919708)
1. Changing patterns of alpha agonist medication use in children and adolescents 2009-2011.
Fiks AG; Mayne SL; Song L; Steffes J; Liu W; McCarn B; Margolis B; Grimes A; Gotlieb E; Localio R; Ross ME; Grundmeier RW; Wasserman R; Leslie LK
J Child Adolesc Psychopharmacol; 2015 May; 25(4):362-7. PubMed ID: 25919708
[TBL] [Abstract][Full Text] [Related]
2. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
3. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
Sallee F; Connor DF; Newcorn JH
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
[TBL] [Abstract][Full Text] [Related]
4. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
Betts KA; Sikirica V; Hodgkins P; Zhou Z; Xie J; DeLeon A; Erder MH; Wu EQ
J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):260-8. PubMed ID: 24839998
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Sallee FR; Lyne A; Wigal T; McGough JJ
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
[TBL] [Abstract][Full Text] [Related]
7. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
Sallee FR
Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
[TBL] [Abstract][Full Text] [Related]
8. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
10. Decreased use of clonidine following treatment with atomoxetine in children with ADHD.
Johnston JA; Ye W; Van Brunt DL; Pohl G; Sumner CR
J Clin Psychopharmacol; 2006 Aug; 26(4):389-95. PubMed ID: 16855457
[TBL] [Abstract][Full Text] [Related]
11. An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
Boon-yasidhi V; Kim YS; Scahill L
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S156-62. PubMed ID: 16856436
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
Scahill L; Chappell PB; Kim YS; Schultz RT; Katsovich L; Shepherd E; Arnsten AF; Cohen DJ; Leckman JF
Am J Psychiatry; 2001 Jul; 158(7):1067-74. PubMed ID: 11431228
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
14. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Rizzo R; Martino D
Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
[TBL] [Abstract][Full Text] [Related]
15. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.
Lawson KA; Johnsrud M; Hodgkins P; Sasané R; Crismon ML
Clin Ther; 2012 Apr; 34(4):944-956.e4. PubMed ID: 22444786
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
Moungnoi P; Maipang P
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
19. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
20. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]